Published in J Immunol on June 26, 2013
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res (2014) 0.90
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent. Cancer Immunol Res (2015) 0.88
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity (2016) 0.88
Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol (2014) 0.85
Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci (2015) 0.84
Coinfection with Streptococcus pneumoniae negatively modulates the size and composition of the ongoing influenza-specific CD8⁺ T cell response. J Immunol (2014) 0.83
T-cell exhaustion in allograft rejection and tolerance. Curr Opin Organ Transplant (2015) 0.82
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov (2016) 0.82
Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology (2016) 0.81
Dendritic cell-based vaccines: Shining the spotlight on signal 3. Oncoimmunology (2013) 0.80
IL-12 is required for mTOR regulation of memory CTLs during viral infection. Genes Immun (2014) 0.78
Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol (2015) 0.77
Therapeutic targeting of the inflammome. Biochem Pharmacol (2014) 0.76
IL-12 Signals through the TCR To Support CD8 Innate Immune Responses. J Immunol (2016) 0.76
IL-1βR-dependent priming of antitumor CD4(+) T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria. Oncoimmunology (2015) 0.76
The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy. Front Immunol (2015) 0.75
miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget (2016) 0.75
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ. J Immunol (2016) 0.75
Exhaustion-associated regulatory regions in CD8(+) tumor-infiltrating T cells. Proc Natl Acad Sci U S A (2017) 0.75
CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. Oncotarget (2016) 0.75
Effector functions of memory CTLs can be affected by signals received during reactivation. Immunol Res (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med (2005) 6.59
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev (2006) 4.60
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity (2011) 2.49
CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol (2003) 2.32
Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol (2009) 2.15
Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol (2009) 2.08
CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol (2006) 1.92
NFATc1 regulates PD-1 expression upon T cell activation. J Immunol (2008) 1.81
The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol (2009) 1.71
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 1.64
The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog (2013) 1.23
Negative regulation of T-cell function by PD-1. Crit Rev Immunol (2004) 1.11
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol (2005) 3.89
Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med (2003) 3.21
Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 2.44
CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol (2003) 2.32
Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol (2009) 2.15
Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol (2009) 2.08
Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity (2013) 1.49
IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J Immunol (2007) 1.45
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp Med (2007) 1.44
Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J Immunol (2005) 1.36
T cell receptor cross-reactivity between similar foreign and self peptides influences naive cell population size and autoimmunity. Immunity (2015) 1.29
Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J Immunol (2002) 1.26
Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol (2002) 1.24
CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J Immunol (2005) 1.23
Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol (2005) 1.23
Signal 3 availability limits the CD8 T cell response to a solid tumor. J Immunol (2007) 1.16
Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14
A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol (2007) 1.12
Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J Immunol (2002) 1.04
PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes (2013) 1.04
Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res (2004) 1.00
Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice. J Immunol (2013) 1.00
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res (2011) 0.98
Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol (2008) 0.98
Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. J Leukoc Biol (2004) 0.94
In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol (2003) 0.93
ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation. J Immunol (2013) 0.91
The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo. J Immunol (2002) 0.90
Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol (2009) 0.90
The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses. Int Immunol (2007) 0.89
Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance induction. J Immunol (2008) 0.89
A protease-dependent mechanism for initiating T-dependent B cell responses to large particulate antigens. J Immunol (2010) 0.88
Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol (2006) 0.85
Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood (2004) 0.85
The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness). J Immunol (2002) 0.84
Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors. Immunol Res (2002) 0.84
Immunoneutralization of chemokines for the prevention and treatment of central nervous system autoimmune disease. Methods (2003) 0.83
Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function. J Immunol (2012) 0.83
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest (2016) 0.83
Multistage T cell-dendritic cell interactions control optimal CD4 T cell activation through the ADAP-SKAP55-signaling module. J Immunol (2013) 0.81
Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol (2008) 0.80
T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. JCI Insight (2017) 0.75